Brief: Bridge Biotherapeutics Announces First Patient Dosed In Its Phase 2A Clinical Trial Of BBT-877
12/04/2023 23:27
April 12 (Reuters) - Bridge Biotherapeutics Inc
288330.KQ :
* BRIDGE BIOTHERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
ITS
PHASE 2A CLINICAL TRIAL OF BBT-877, A POTENT AUTOTAXIN INHIBITOR
FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
* BRIDGE BIOTHERAPEUTICS INC - MAINTAINS ITS GUIDANCE THAT
IT
EXPECTS TO ANNOUNCE TOPLINE DATA IN SECOND HALF OF 2023
Source text for Eikon: ID:nPn14by5sa
Further company coverage: 288330.KQ
((Reuters.Brief@thomsonreuters.com;))
Recent news on Parataxis Korea
See all newsBrief: Parataxis, Bridge Biotherapeutics Ink Deal to List Bitcoin Treasury Firm on Korea's KOSDAQ
Brief: Bridge Biotherapeutics Announces Completion Of Enrollment In The Phase 2A Clinical Study Of BBT-877 For The Treatment Of Idiopathic Pulmonary Fibrosis
Brief: Bridge Biotherapeutics Launches A Research Collaboration With Emory University School Of Medicine
Brief: Bridge Biotherapeutics Announces A Research Collaboration With The University Of Colorado School Of Medicine
Brief: Bridge Biotherapeutics To Conduct Capital Increase Of 2 Billion Won For Operational Funds